Symbols / RPRX Stock $54.52 -2.00% Royalty Pharma plc
RPRX (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-07 | main | Citigroup | Buy → Buy | $66 |
| 2026-05-07 | main | JP Morgan | Overweight → Overweight | $58 |
| 2026-04-21 | main | UBS | Buy → Buy | $57 |
| 2026-04-10 | main | Morgan Stanley | Overweight → Overweight | $63 |
| 2026-01-30 | up | UBS | Neutral → Buy | $49 |
| 2026-01-27 | main | Citigroup | Buy → Buy | $50 |
| 2025-12-11 | main | TD Cowen | Buy → Buy | $45 |
| 2025-10-10 | main | Morgan Stanley | Overweight → Overweight | $54 |
| 2025-09-30 | init | Goldman Sachs | — → Buy | $42 |
| 2025-07-22 | main | Citigroup | Buy → Buy | $42 |
| 2025-07-10 | main | Morgan Stanley | Overweight → Overweight | $54 |
| 2024-10-25 | main | Citigroup | Buy → Buy | $40 |
| 2024-08-14 | main | Goldman Sachs | Buy → Buy | $51 |
| 2024-07-11 | main | Morgan Stanley | Overweight → Overweight | $51 |
| 2024-06-03 | down | UBS | Buy → Neutral | $28 |
| 2024-04-12 | main | B of A Securities | Buy → Buy | $38 |
| 2024-02-20 | main | JP Morgan | Overweight → Overweight | $42 |
| 2024-02-20 | main | Goldman Sachs | Buy → Buy | $50 |
| 2023-11-09 | main | Morgan Stanley | Overweight → Overweight | $57 |
| 2023-10-11 | main | Morgan Stanley | Overweight → Overweight | $54 |
- Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat Wed, 10 Jun 2026 12
- Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings? - StockStory ue, 09 Jun 2026 09
- Director at Royalty Pharma (RPRX) receives 4,545 restricted stock units grant - Stock Titan Mon, 08 Jun 2026 20
- ROYALTY PHARMA PLC- CL A (RPRX) Stock Chart - ChartMill Mon, 08 Jun 2026 07
- Royalty Pharma (RPRX) Valuation Check After Strong Share Price Momentum And Royalty Growth Potential - Yahoo Finance Mon, 25 May 2026 07
- (RPRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily Sat, 06 Jun 2026 14
- CenterBook Partners LP Has $2.71 Million Position in Royalty Pharma PLC $RPRX - MarketBeat Wed, 10 Jun 2026 08
- Royalty Pharma (RPRX) director Carole Ho awarded 4,545 restricted shares - Stock Titan Mon, 08 Jun 2026 20
- Royalty Pharma (RPRX) director awarded 4,545 restricted stock units in equity grant - Stock Titan Mon, 08 Jun 2026 20
- TD Asset Management Inc Has $9.19 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat Wed, 10 Jun 2026 11
- Royalty Pharma (RPRX) director Bonnie Bassler awarded 4,545 RSUs, raising holdings to 78,492 shares - Stock Titan Mon, 08 Jun 2026 20
- Royalty Pharma PLC $RPRX Stock Position Increased by Brandywine Global Investment Management LLC - MarketBeat Mon, 08 Jun 2026 07
- Royalty Pharma (RPRX) director receives 4,545 share unit award - Stock Titan Mon, 08 Jun 2026 20
- Prudential PLC Decreases Stock Position in Royalty Pharma PLC $RPRX - MarketBeat ue, 09 Jun 2026 09
- Royalty Pharma (RPRX) awards 4,545 RSUs to board director - Stock Titan Mon, 08 Jun 2026 20
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
2,378.19
+5.06%
|
2,263.58
-3.86%
|
2,354.55
+5.24%
|
2,237.22
|
| Operating Revenue |
|
2,378.19
+5.06%
|
2,263.58
-3.86%
|
2,354.55
+5.24%
|
2,237.22
|
| Operating Expense |
|
818.67
-15.70%
|
971.13
+12.61%
|
862.40
-34.38%
|
1,314.32
|
| Research And Development |
|
452.00
+22500.00%
|
2.00
-96.15%
|
52.00
-70.64%
|
177.11
|
| Selling General And Administration |
|
573.48
+142.31%
|
236.67
-5.24%
|
249.75
+9.87%
|
227.30
|
| General And Administrative Expense |
|
573.48
+142.31%
|
236.67
-5.24%
|
249.75
+9.87%
|
227.30
|
| Other Gand A |
|
573.48
+142.31%
|
236.67
-5.24%
|
249.75
+9.87%
|
227.30
|
| Other Operating Expenses |
|
-295.84
-140.39%
|
732.46
+30.64%
|
560.66
-38.00%
|
904.24
|
| Total Expenses |
|
818.67
-15.70%
|
971.13
+12.61%
|
862.40
-34.38%
|
1,314.32
|
| Operating Income |
|
1,559.52
+20.66%
|
1,292.44
-13.38%
|
1,492.15
+61.68%
|
922.89
|
| Total Operating Income As Reported |
|
1,559.52
+20.66%
|
1,292.44
-13.38%
|
1,492.15
+385.94%
|
307.06
|
| EBITDA |
|
1,635.71
+5.10%
|
1,556.33
-17.54%
|
1,887.28
+345.43%
|
423.69
|
| Normalized EBITDA |
|
1,611.70
+17.83%
|
1,367.87
-12.96%
|
1,571.59
+59.85%
|
983.17
|
| Reconciled Depreciation |
|
3.85
|
0.00
|
0.00
-100.00%
|
5.67
|
| EBIT |
|
1,631.86
+4.85%
|
1,556.33
-17.54%
|
1,887.28
+351.47%
|
418.02
|
| Total Unusual Items |
|
24.01
-87.26%
|
188.46
-40.30%
|
315.69
+156.43%
|
-559.47
|
| Total Unusual Items Excluding Goodwill |
|
24.01
-87.26%
|
188.46
-40.30%
|
315.69
+156.43%
|
-559.47
|
| Special Income Charges |
|
—
|
0.00
|
0.00
+100.00%
|
-615.83
|
| Write Off |
|
—
|
0.00
|
0.00
-100.00%
|
615.83
|
| Net Income |
|
770.95
-10.25%
|
858.98
-24.31%
|
1,134.83
+2549.50%
|
42.83
|
| Pretax Income |
|
1,324.19
-0.50%
|
1,330.81
-21.72%
|
1,700.09
+638.96%
|
230.06
|
| Net Non Operating Interest Income Expense |
|
-274.07
-53.83%
|
-178.17
-55.07%
|
-114.90
-4.81%
|
-109.63
|
| Interest Expense Non Operating |
|
307.66
+36.43%
|
225.51
+20.47%
|
187.19
-0.41%
|
187.96
|
| Net Interest Income |
|
-274.07
-53.83%
|
-178.17
-55.07%
|
-114.90
-4.81%
|
-109.63
|
| Interest Expense |
|
307.66
+36.43%
|
225.51
+20.47%
|
187.19
-0.41%
|
187.96
|
| Interest Income Non Operating |
|
33.59
-29.05%
|
47.34
-34.51%
|
72.29
-7.72%
|
78.33
|
| Interest Income |
|
33.59
-29.05%
|
47.34
-34.51%
|
72.29
-7.72%
|
78.33
|
| Other Income Expense |
|
38.75
-82.11%
|
216.54
-32.93%
|
322.83
+155.36%
|
-583.20
|
| Other Non Operating Income Expenses |
|
-14.35
-839.07%
|
-1.53
+92.97%
|
-21.74
-47.32%
|
-14.76
|
| Gain On Sale Of Security |
|
24.01
-87.26%
|
188.46
-40.30%
|
315.69
+460.20%
|
56.35
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
1,324.19
-0.50%
|
1,330.81
-21.72%
|
1,700.09
+638.96%
|
230.06
|
| Net Income From Continuing Operation Net Minority Interest |
|
770.95
-10.25%
|
858.98
-24.31%
|
1,134.83
+2549.50%
|
42.83
|
| Net Income From Continuing And Discontinued Operation |
|
770.95
-10.25%
|
858.98
-24.31%
|
1,134.83
+2549.50%
|
42.83
|
| Net Income Continuous Operations |
|
1,324.19
-0.50%
|
1,330.81
-21.72%
|
1,700.09
+638.96%
|
230.06
|
| Minority Interests |
|
-553.25
-17.26%
|
-471.83
+16.53%
|
-565.25
-201.90%
|
-187.23
|
| Normalized Income |
|
746.94
+11.40%
|
670.53
-18.14%
|
819.14
+36.00%
|
602.31
|
| Net Income Common Stockholders |
|
770.95
-10.25%
|
858.98
-24.31%
|
1,134.83
+2549.50%
|
42.83
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
-392.73
|
—
|
| Diluted EPS |
|
1.37
-5.47%
|
1.45
-42.84%
|
2.53
+2430.00%
|
0.10
|
| Basic EPS |
|
1.80
-6.62%
|
1.93
-24.17%
|
2.54
+2440.00%
|
0.10
|
| Basic Average Shares |
|
428.67
-3.88%
|
445.99
-0.36%
|
447.60
+2.20%
|
437.96
|
| Diluted Average Shares |
|
564.00
-5.05%
|
594.00
-1.48%
|
602.90
+37.66%
|
437.97
|
| Diluted NI Availto Com Stockholders |
|
1,005.52
-11.48%
|
1,135.88
-25.64%
|
1,527.56
+3466.40%
|
42.83
|
| Average Dilution Earnings |
|
234.57
-15.28%
|
276.89
-29.49%
|
392.73
|
—
|
| Amortization |
|
—
|
0.00
|
0.00
-100.00%
|
5.67
|
| Amortization Of Intangibles Income Statement |
|
—
|
0.00
|
0.00
-100.00%
|
5.67
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
0.00
|
0.00
-100.00%
|
5.67
|
| Depreciation And Amortization In Income Statement |
|
—
|
0.00
|
0.00
-100.00%
|
5.67
|
| Earnings From Equity Interest |
|
29.09
-1.76%
|
29.61
+2.52%
|
28.88
+421.88%
|
-8.97
|
| Provision For Doubtful Accounts |
|
89.03
|
0.00
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
19,620.78
+7.67%
|
18,222.72
+11.24%
|
16,381.85
-2.57%
|
16,813.47
|
| Current Assets |
|
1,528.09
-15.21%
|
1,802.14
+41.43%
|
1,274.19
-50.13%
|
2,554.91
|
| Cash Cash Equivalents And Short Term Investments |
|
1,491.88
-15.76%
|
1,771.00
+43.55%
|
1,233.75
-49.18%
|
2,427.79
|
| Cash And Cash Equivalents |
|
618.70
-33.40%
|
929.03
+94.76%
|
477.01
-72.12%
|
1,710.75
|
| Other Short Term Investments |
|
873.19
+3.71%
|
841.97
+11.26%
|
756.74
+5.54%
|
717.04
|
| Receivables |
|
29.32
+8.76%
|
26.96
+20.31%
|
22.41
-38.78%
|
36.60
|
| Other Receivables |
|
29.32
+8.76%
|
26.96
+20.31%
|
22.41
-38.78%
|
36.60
|
| Other Current Assets |
|
6.89
+64.63%
|
4.19
-76.79%
|
18.04
-80.07%
|
90.52
|
| Total Non Current Assets |
|
18,092.69
+10.18%
|
16,420.58
+8.69%
|
15,107.66
+5.96%
|
14,258.56
|
| Goodwill And Other Intangible Assets |
|
924.63
|
0.00
|
—
|
0.00
|
| Goodwill |
|
924.63
|
0.00
|
—
|
—
|
| Other Intangible Assets |
|
—
|
—
|
—
|
—
|
| Investments And Advances |
|
17,088.76
+4.28%
|
16,387.04
+8.52%
|
15,101.14
+6.13%
|
14,228.93
|
| Long Term Equity Investment |
|
289.97
-23.58%
|
379.42
+0.94%
|
375.89
-5.36%
|
397.18
|
| Other Non Current Assets |
|
79.29
+136.46%
|
33.53
+414.17%
|
6.52
-77.99%
|
29.63
|
| Total Liabilities Net Minority Interest |
|
9,905.84
+25.70%
|
7,880.35
+25.13%
|
6,297.56
-13.59%
|
7,288.09
|
| Current Liabilities |
|
636.21
-49.25%
|
1,253.62
+676.82%
|
161.38
-86.17%
|
1,166.78
|
| Payables And Accrued Expenses |
|
203.05
+8.44%
|
187.24
+24.83%
|
150.00
-4.38%
|
156.87
|
| Payables |
|
92.23
+3.42%
|
89.18
-9.30%
|
98.32
-4.27%
|
102.71
|
| Accounts Payable |
|
19.40
+45.13%
|
13.37
-11.84%
|
15.16
+91.82%
|
7.91
|
| Dividends Payable |
|
72.83
-3.94%
|
75.81
-8.83%
|
83.16
-12.29%
|
94.80
|
| Current Accrued Expenses |
|
110.82
+13.01%
|
98.06
+89.74%
|
51.68
-4.58%
|
54.16
|
| Employee Benefits |
|
577.87
|
0.00
|
—
|
—
|
| Current Debt And Capital Lease Obligation |
|
380.00
-61.92%
|
997.77
|
—
|
997.51
|
| Current Debt |
|
380.00
-61.92%
|
997.77
|
—
|
997.51
|
| Other Current Borrowings |
|
—
|
997.77
|
—
|
997.51
|
| Other Current Liabilities |
|
53.16
-22.50%
|
68.60
+503.08%
|
11.38
-8.27%
|
12.40
|
| Total Non Current Liabilities Net Minority Interest |
|
9,269.63
+39.88%
|
6,626.73
+7.99%
|
6,136.19
+0.24%
|
6,121.31
|
| Long Term Debt And Capital Lease Obligation |
|
8,570.92
+29.57%
|
6,614.65
+7.81%
|
6,135.28
+0.27%
|
6,118.81
|
| Long Term Debt |
|
8,570.92
+29.57%
|
6,614.65
+7.81%
|
6,135.28
+0.27%
|
6,118.81
|
| Other Non Current Liabilities |
|
120.84
+900.36%
|
12.08
+1242.22%
|
0.90
-64.00%
|
2.50
|
| Stockholders Equity |
|
6,476.90
-6.76%
|
6,946.58
+6.44%
|
6,526.50
+15.96%
|
5,628.15
|
| Common Stock Equity |
|
6,476.90
-6.76%
|
6,946.58
+6.44%
|
6,526.50
+15.96%
|
5,628.15
|
| Capital Stock |
|
0.11
-1.85%
|
0.11
+0.00%
|
0.11
+0.93%
|
0.11
|
| Common Stock |
|
0.11
-1.85%
|
0.11
+0.00%
|
0.11
+0.93%
|
0.11
|
| Share Issued |
|
428.67
-3.88%
|
445.99
-0.16%
|
446.69
+0.80%
|
443.17
|
| Ordinary Shares Number |
|
428.67
-3.88%
|
445.99
-0.16%
|
446.69
+0.80%
|
443.17
|
| Additional Paid In Capital |
|
4,123.09
+0.48%
|
4,103.48
+2.29%
|
4,011.43
+9.42%
|
3,666.16
|
| Retained Earnings |
|
2,356.32
-17.20%
|
2,845.65
+13.03%
|
2,517.58
+28.14%
|
1,964.69
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
0.00
|
0.00
|
0.00
|
| Treasury Stock |
|
2.61
-1.88%
|
2.66
+1.26%
|
2.63
-6.31%
|
2.81
|
| Minority Interest |
|
3,238.04
-4.65%
|
3,395.78
-4.55%
|
3,557.79
-8.71%
|
3,897.22
|
| Other Equity Adjustments |
|
—
|
—
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
9,714.94
-6.07%
|
10,342.37
+2.56%
|
10,084.29
+5.87%
|
9,525.37
|
| Total Capitalization |
|
15,047.82
+10.96%
|
13,561.23
+7.10%
|
12,661.78
+7.79%
|
11,746.96
|
| Working Capital |
|
891.88
+62.60%
|
548.52
-50.71%
|
1,112.82
-19.83%
|
1,388.12
|
| Invested Capital |
|
15,427.82
+5.97%
|
14,559.01
+14.98%
|
12,661.78
-0.65%
|
12,744.47
|
| Total Debt |
|
8,950.92
+17.58%
|
7,612.43
+24.08%
|
6,135.28
-13.79%
|
7,116.32
|
| Net Debt |
|
8,332.22
+24.67%
|
6,683.40
+18.12%
|
5,658.27
+4.67%
|
5,405.57
|
| Net Tangible Assets |
|
5,552.27
-20.07%
|
6,946.58
+6.44%
|
6,526.50
+15.96%
|
5,628.15
|
| Tangible Book Value |
|
5,552.27
-20.07%
|
6,946.58
+6.44%
|
6,526.50
+15.96%
|
5,628.15
|
| Available For Sale Securities |
|
16,798.79
+4.94%
|
16,007.62
+8.71%
|
14,725.24
+6.46%
|
13,831.75
|
| Interest Payable |
|
110.82
+13.01%
|
98.06
+89.74%
|
51.68
-4.58%
|
54.16
|
| Investmentin Financial Assets |
|
16,798.79
+4.94%
|
16,007.62
+8.71%
|
14,725.24
+6.46%
|
13,831.75
|
| Investments In Other Ventures Under Equity Method |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
2,489.82
-10.08%
|
2,768.99
-7.32%
|
2,987.80
+39.36%
|
2,143.98
|
| Cash Flow From Continuing Operating Activities |
|
2,489.82
-10.08%
|
2,768.99
-7.32%
|
2,987.80
+39.36%
|
2,143.98
|
| Net Income From Continuing Operations |
|
1,324.19
-0.50%
|
1,330.81
-21.72%
|
1,700.09
+638.96%
|
230.06
|
| Depreciation Amortization Depletion |
|
3.85
|
0.00
|
0.00
-100.00%
|
5.67
|
| Depreciation |
|
3.85
|
0.00
|
0.00
|
—
|
| Amortization Cash Flow |
|
—
|
0.00
|
0.00
-100.00%
|
5.67
|
| Depreciation And Amortization |
|
3.85
|
0.00
|
0.00
-100.00%
|
5.67
|
| Amortization Of Intangibles |
|
—
|
0.00
|
0.00
-100.00%
|
5.67
|
| Other Non Cash Items |
|
3,396.69
+13.07%
|
3,004.08
-7.36%
|
3,242.82
+30.43%
|
2,486.26
|
| Stock Based Compensation |
|
289.89
+12267.49%
|
2.34
-0.55%
|
2.36
+8.62%
|
2.17
|
| Provisionand Write Offof Assets |
|
-206.81
-128.23%
|
732.46
+30.64%
|
560.66
-38.00%
|
904.24
|
| Asset Impairment Charge |
|
—
|
0.00
|
0.00
-100.00%
|
615.83
|
| Operating Gains Losses |
|
-2,314.25
+2.25%
|
-2,367.49
+6.88%
|
-2,542.32
-17.05%
|
-2,172.06
|
| Gain Loss On Investment Securities |
|
-2,285.16
+2.25%
|
-2,337.88
+6.99%
|
-2,513.44
-15.22%
|
-2,181.45
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
-17.15
-132.13%
|
53.38
+891.88%
|
5.38
-83.52%
|
32.66
|
| Change In Receivables |
|
-2.36
+48.14%
|
-4.55
-199.21%
|
-1.52
+67.94%
|
-4.74
|
| Change In Payables And Accrued Expense |
|
-4.99
-111.33%
|
44.09
+1073.86%
|
3.76
+400.96%
|
-1.25
|
| Change In Accrued Expense |
|
8.93
-80.74%
|
46.38
+1970.16%
|
-2.48
+29.82%
|
-3.53
|
| Change In Payable |
|
-13.93
-508.21%
|
-2.29
-136.72%
|
6.24
+172.79%
|
2.29
|
| Change In Account Payable |
|
-13.93
-508.21%
|
-2.29
-136.72%
|
6.24
+172.79%
|
2.29
|
| Change In Other Current Assets |
|
-7.45
-153.79%
|
13.84
+339.91%
|
3.15
-91.86%
|
38.65
|
| Change In Other Current Liabilities |
|
-2.35
|
0.00
|
0.00
|
—
|
| Investing Cash Flow |
|
-1,614.18
+39.73%
|
-2,678.11
-29.20%
|
-2,072.79
-101.35%
|
-1,029.42
|
| Cash Flow From Continuing Investing Activities |
|
-1,614.18
+39.73%
|
-2,678.11
-29.20%
|
-2,072.79
-101.35%
|
-1,029.42
|
| Net Investment Purchase And Sale |
|
-1,364.65
+47.87%
|
-2,617.84
-25.27%
|
-2,089.69
-104.97%
|
-1,019.52
|
| Purchase Of Investment |
|
-1,931.16
+29.42%
|
-2,736.20
-29.34%
|
-2,115.52
+17.53%
|
-2,565.07
|
| Sale Of Investment |
|
566.50
+378.62%
|
118.36
+358.21%
|
25.83
-98.33%
|
1,545.54
|
| Net Business Purchase And Sale |
|
-74.42
-579.29%
|
-10.96
+12.65%
|
-12.54
-26.74%
|
-9.90
|
| Purchase Of Business |
|
-74.42
-579.29%
|
-10.96
+12.65%
|
-12.54
-26.74%
|
-9.90
|
| Net Other Investing Changes |
|
-280.26
-284.12%
|
-72.96
-405.34%
|
-14.44
|
—
|
| Financing Cash Flow |
|
-1,185.97
-428.39%
|
361.14
+116.81%
|
-2,148.75
-127.42%
|
-944.86
|
| Cash Flow From Continuing Financing Activities |
|
-1,185.97
-428.39%
|
361.14
+116.81%
|
-2,148.75
-127.42%
|
-944.86
|
| Net Issuance Payments Of Debt |
|
954.48
-35.12%
|
1,471.23
+247.12%
|
-1,000.00
|
0.00
|
| Issuance Of Debt |
|
3,229.47
+119.51%
|
1,471.23
+320.35%
|
350.00
|
0.00
|
| Repayment Of Debt |
|
-2,275.00
|
0.00
+100.00%
|
-1,350.00
|
0.00
|
| Long Term Debt Issuance |
|
3,229.47
+119.51%
|
1,471.23
+320.35%
|
350.00
|
0.00
|
| Long Term Debt Payments |
|
-2,275.00
|
0.00
+100.00%
|
-1,350.00
|
0.00
|
| Net Long Term Debt Issuance |
|
954.48
-35.12%
|
1,471.23
+247.12%
|
-1,000.00
|
0.00
|
| Short Term Debt Issuance |
|
—
|
—
|
350.00
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
-350.00
|
0.00
|
| Net Short Term Debt Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
-1,227.38
-434.46%
|
-229.65
+24.65%
|
-304.76
|
0.00
|
| Common Stock Payments |
|
-1,227.38
-434.46%
|
-229.65
+24.65%
|
-304.76
|
0.00
|
| Common Stock Dividend Paid |
|
-378.25
-0.47%
|
-376.46
-5.06%
|
-358.33
-7.50%
|
-333.32
|
| Cash Dividends Paid |
|
-378.25
-0.47%
|
-376.46
-5.06%
|
-358.33
-7.50%
|
-333.32
|
| Repurchase Of Capital Stock |
|
-1,227.38
-434.46%
|
-229.65
+24.65%
|
-304.76
|
0.00
|
| Net Other Financing Charges |
|
-534.81
-6.12%
|
-503.97
-3.77%
|
-485.67
+20.58%
|
-611.53
|
| Changes In Cash |
|
-310.33
-168.65%
|
452.02
+136.64%
|
-1,233.74
-827.00%
|
169.70
|
| Beginning Cash Position |
|
929.03
+94.76%
|
477.01
-72.12%
|
1,710.75
+11.01%
|
1,541.05
|
| End Cash Position |
|
618.70
-33.40%
|
929.03
+94.76%
|
477.01
-72.12%
|
1,710.75
|
| Free Cash Flow |
|
2,489.82
-10.08%
|
2,768.99
-7.32%
|
2,987.80
+39.36%
|
2,143.98
|
| Change In Interest Payable |
|
8.93
-80.74%
|
46.38
+1970.16%
|
-2.48
+29.82%
|
-3.53
|
| Common Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Dividend Received CFO |
|
13.40
+0.00%
|
13.40
-28.83%
|
18.82
-51.91%
|
39.14
|
| Dividends Received CFI |
|
105.15
+344.77%
|
23.64
-46.13%
|
43.88
|
0.00
|
| Earnings Losses From Equity Investments |
|
-29.09
+1.76%
|
-29.61
-2.52%
|
-28.88
-421.88%
|
8.97
|
| Issuance Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-06-08 View
- 42026-06-08 View
- 42026-06-08 View
- 42026-06-08 View
- 42026-06-08 View
- 42026-06-08 View
- 42026-06-08 View
- 42026-06-08 View
- 8-K2026-06-04 View
- 42026-05-28 View
- 8-K2026-05-28 View
- 42026-05-21 View
- 42026-05-15 View
- 42026-05-15 View
- 42026-05-08 View
- 42026-05-08 View
- 42026-05-08 View
- 42026-05-08 View
- 10-Q2026-05-06 View
- 8-K2026-05-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|